drugset / Trial / NCT06125080
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
Timeline
- Start
- 2023-10-30
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | — |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | — |